| Prospects for mucosal vaccine: shutting the door on SARS-CoV-2 R Mudgal, S Nehul, S Tomar Human vaccines & immunotherapeutics 16 (12), 2921-2931, 2020 | 117 | 2020 |
| Alphavirus capsid protease inhibitors as potential antiviral agents for Chikungunya infection B Fatma, R Kumar, VA Singh, S Nehul, R Sharma, P Kesari, RJ Kuhn, ... Antiviral Research 179, 104808, 2020 | 44 | 2020 |
| Identification and evaluation of antiviral potential of thymoquinone, a natural compound targeting Chikungunya virus capsid protein R Kumar, S Nehul, A Singh, S Tomar Virology 561, 36-46, 2021 | 21 | 2021 |
| Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS‐COV‐2 targeting main protease and papain‐like protease S Choudhary, S Nehul, A Singh, PK Panda, P Kumar, GK Sharma, ... IUBMB life 76 (5), 228-241, 2024 | 8 | 2024 |
| A retrospective study showing a high rate of seropositivity against SARS-CoV-2 in wild felines in India R Borkakoti, M Karikalan, SK Nehul, HR Jogi, K Sharma, S Nautiyal, ... Archives of Virology 168 (4), 109, 2023 | 4 | 2023 |
| Structure-guided mutations in CDRs for enhancing the affinity of neutralizing SARS-CoV-2 nanobody V Singh, M Bhutkar, S Choudhary, S Nehul, R Kumar, J Singla, P Kumar, ... Biochemical and Biophysical Research Communications 734, 150746, 2024 | 3 | 2024 |
| Disruption of Molecular Interactions between the G3BP1 Stress Granule Host Protein and the Nucleocapsid (NTD-N) Protein Impedes SARS-CoV-2 Virus Replication P Dhaka, A Singh, S Nehul, S Choudhary, PK Panda, GK Sharma, ... Biochemistry, 2024 | 2 | 2024 |
| Designing and bioengineering of CDRs with higher affinity against receptor-binding domain (RBD) of SARS-CoV-2 Omicron variant V Singh, S Choudhary, M Bhutkar, S Nehul, S Ali, J Singla, P Kumar, ... International Journal of Biological Macromolecules 290, 138751, 2025 | 1 | 2025 |
| Structural and Mechanistic Insights into the Main Protease (Mpro) Dimer Interface Destabilization Inhibitor: Unveiling New Therapeutic Avenues against SARS-CoV-2 A Singh, K Jangid, S Nehul, P Dhaka, R Rani, A Pareek, GK Sharma, ... Biochemistry, 2024 | 1 | 2024 |
| Chimeric chikungunya virus-like particles with surface exposed SARS-CoV-2 RBD elicits potent immunogenic responses in mice VA Singh, S Nehul, CS Kumar, M Banerjee, P Kumar, G Sharma, S Tomar bioRxiv, 2023.01. 29.526074, 2023 | 1 | 2023 |
| Revealing and evaluation of antivirals targeting multiple druggable sites of RdRp complex in SARS-CoV-2 R Rani, S Nehul, S Choudhary, A Upadhyay, GK Sharma, P Kumar, ... bioRxiv, 2023.07. 24.550324, 2023 | 1 | 2023 |
| Activity profiling of deubiquitinating inhibitors-bound to SARS-CoV-2 papain like protease with antiviral efficacy in murine infection model S Choudhary, S Nehul, SK Nagaraj, R Narayan, S Verma, S Sharma, ... bioRxiv, 2022.11. 11.516107, 2022 | 1 | 2022 |
| Enhancing affinity of neutralizing SARS-CoV-2 nanobody through facile structure-guided mutations in CDRs V Singh, M Bhutkar, S Choudhary, S Nehul, R Kumar, J Singla, P Kumar, ... bioRxiv, 2024.05. 13.593833, 2024 | | 2024 |
| In Vitro and in Vivo Evaluation Tools of SARS-CoV-2 Antiviral Drugs GK Sharma, S Nehul, S Choudhary, S Mahajan Advances in Antiviral Research, 287-305, 2024 | | 2024 |
| Repurposing efavirenz, the HIV antiretroviral drug for Chikungunya virus infection S Nehul, R Rani, PK Panda, P Kumar, S Tomar bioRxiv, 2023.09. 29.560149, 2023 | | 2023 |
| Repurposing HIV antiretroviral drug efavirenz against chikungunya virus S Nehul, R Rani, S Tomar | | 2023 |
